OBJECTIVES: To evaluate the cost-effectiveness of somatostatin analogues in the treatment of acromegaly in Colombia. METHODS: Cost-effectiveness of both somatostatin analogues, octreotide and lanreotide, was estimated using decision analysis. Response to treatment in the model was derived from a recent meta-analysis. Costs and resource utilization included only data directly related to the treatment of the acromegaly during the 2 year time-horizon in Colombia. Transition probabilities were calculated based on the efficacy results from clinical trials pooled in the meta-analysis. The model’s effectiveness outcome is patients who are successfully controlled in terms of their Growth Hormone <2.5 mcg. RESULTS: Using the estimated prevalence of the disease in Colombia, a hypothetical cohort of 2,503 subjects with acromegaly with an average age of 50 years was included in the model. The total annual medical treatment costs for the octreotide group were COP$ 162,802 million, compared to the total annual costs for the lanreotide group of COP$ 214,047 million. In the octreotide arm 65.3% of the patients and in the lanreotide arm 59.5% of the patients were successfully controlled. The estimated number of deaths was 164 and 168 for the groups with octreotide and lanreotide, respectively. Because the costs are lower and the effectiveness is higher for octreotide in comparison with lanreotide, octreotide is more cost-effective (dominant).  Probabilistic sensitivity analyses were consistent showing octreotide as the most cost-effective option. . CONCLUSIONS: Costs and effects of octreotide compare favorably to those of lanreotide in the treatment of acromegaly in Colombia. Sensitivity analysis showed that despite the uncertainty in cost-effectiveness ratio this result is robust